This evidence supports the notion that c-Met represents a primary potential target in NSCLC, also demonstrating a high clinical relevance in the treatment with EGFR-TKIs, since previous research showed that mutations in the c-Met receptor might cause innate resistance to antibodies [54]. The gene discussed is MET; the disease is non-small cell lung carcinoma.